Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Merit Ester Cudkowicz, M.D.

TitleJulieanne Dorn Professor of Neurology
InstitutionMassachusetts General Hospital
DepartmentNeurology
AddressMassachusetts General Hospital
Building 149, Room 2274
149 13th Street
Charlestown MA 02129
Phone617/724-1873
Fax617/724-7290
Other Positions
TitleHead of the Department of Neurology at the Massachusetts General Hospital
InstitutionMassachusetts General Hospital
DepartmentNeurology


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013 Nov; 12(11):1059-67.
    View in: PubMed
  2. Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin EA, Cudkowicz ME. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013 Oct 8; 81(15):1350-5.
    View in: PubMed
  3. Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec; 14(7-8):632-4.
    View in: PubMed
  4. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013; 8(4):e61177.
    View in: PubMed
  5. Cohen-Adad J, Zhao W, Keil B, Ratai EM, Triantafyllou C, Lawson R, Dheel C, Wald LL, Rosen BR, Cudkowicz M, Atassi N. 7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis. Muscle Nerve. 2013 May; 47(5):760-2.
    View in: PubMed
  6. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May; 12(5):435-42.
    View in: PubMed
  7. Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM. SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy. JAMA Neurol. 2013 Feb 1; 70(2):201-7.
    View in: PubMed
  8. Berry JD, Miller R, Moore DH, Cudkowicz ME, Van Den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr; 14(3):162-8.
    View in: PubMed
  9. Gladman M, Cudkowicz M, Zinman L. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol. 2012 Dec; 25(6):735-42.
    View in: PubMed
  10. Andres PL, English R, Mendoza M, Florence J, Malkus E, Schierbecker J, Siener C, Malspeis S, Schoenfeld DA, Munsat TL, Cudkowicz ME. Developing normalized strength scores for neuromuscular research. Muscle Nerve. 2013 Feb; 47(2):177-82.
    View in: PubMed
  11. Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan; 14(1):44-51.
    View in: PubMed
  12. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, Lawson R, Berry J, Krichevsky AM, Cudkowicz ME, Weiner HL. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012 Sep 4; 122(9):3063-87.
    View in: PubMed
  13. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8.
    View in: PubMed
  14. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. What does body mass index measure in amyotrophic lateral sclerosis and why should we care? Muscle Nerve. 2012 Apr; 45(4):612.
    View in: PubMed
  15. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA. A high-density genome-wide association screen of sporadic ALS in US veterans. PLoS One. 2012; 7(3):e32768.
    View in: PubMed
  16. Paganoni S, Zhang M, Quiroz Zárate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012 Sep; 259(9):1923-8.
    View in: PubMed
  17. Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME. Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs. Int J Toxicol. 2012 Jan-Feb; 31(1):58-69.
    View in: PubMed
  18. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M, Glass J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, Sherman A, Steinacker P, Süssmuth S, Teunissen C, Tumani H, Wuolikainen A, Ludolph A. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012 Jan; 13(1):1-10.
    View in: PubMed
  19. Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, Cudkowicz ME. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012 Jan; 45(1):81-5.
    View in: PubMed
  20. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012 Jan; 13(1):110-8.
    View in: PubMed
  21. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Dec; 17(12):1652-6.
    View in: PubMed
  22. van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, Hyman BT, Ivinson AJ, Scherzer CR, Schoenfeld DA, Cudkowicz ME, Brown RH, Bosco DA. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Nov; 12(6):430-8.
    View in: PubMed
  23. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011 Jul; 44(1):20-4.
    View in: PubMed
  24. Atassi N, Cudkowicz ME, Schoenfeld DA. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Jul; 12(4):272-7.
    View in: PubMed
  25. Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011 May; 10(5):481-90.
    View in: PubMed
  26. Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, Cudkowicz M. Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler. 2011 Jan; 12(1):11-6.
    View in: PubMed
  27. Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Mar; 12(2):109-12.
    View in: PubMed
  28. Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011 Jan 15; 300(1-2):23-7.
    View in: PubMed
  29. Royce-Nagel G, Cudkowicz M, Myers D, Nicholson K, Shui A, Schoenfeld D, Huang X, Brown RH. Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Oct; 11(5):492-3.
    View in: PubMed
  30. Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, Glass JD, Peng J. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J Proteome Res. 2010 Oct 1; 9(10):5133-41.
    View in: PubMed
  31. Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord. 2010 Sep 15; 25(12):1924-8.
    View in: PubMed
  32. Atassi N, Ratai EM, Greenblatt DJ, Pulley D, Zhao Y, Bombardier J, Wallace S, Eckenrode J, Cudkowicz M, Dibernardo A. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Dec; 11(6):508-13.
    View in: PubMed
  33. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010 Jul; 42(1):104-11.
    View in: PubMed
  34. Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 May 3; 11(3):259-65.
    View in: PubMed
  35. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 May; 9(5):481-8.
    View in: PubMed
  36. Cudkowicz ME, Swash M. CSF markers in amyotrophic lateral sclerosis: has the time come? Neurology. 2010 Mar 23; 74(12):949-50.
    View in: PubMed
  37. Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010; 11(1-2):178-80.
    View in: PubMed
  38. Lanka V, Wieland S, Barber J, Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs. 2009 Dec; 18(12):1907-18.
    View in: PubMed
  39. Badayan I, Cudkowicz ME. Profound muscle weakness and pain after one dose of actonel. Case Report Med. 2009; 2009:693014.
    View in: PubMed
  40. Qureshi M, Bedlack RS, Cudkowicz ME. Lyme disease serology in amyotrophic lateral sclerosis. Muscle Nerve. 2009 Oct; 40(4):626-8.
    View in: PubMed
  41. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009 Oct-Dec; 10(5-6):324-31.
    View in: PubMed
  42. Harel NY, Cudkowicz ME, Brown RH, Strittmatter SM. Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients. Biomarkers. 2009 Sep; 14(6):414-7.
    View in: PubMed
  43. Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol JL, Cudkowicz M, Leigh PN, Meininger V. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009 Jun; 66(6):758-61.
    View in: PubMed
  44. Bedlack RS, Silani V, Cudkowicz ME. IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. Amyotroph Lateral Scler. 2009 Jun; 10(3):182-4.
    View in: PubMed
  45. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009 Apr; 10(2):99-106.
    View in: PubMed
  46. Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, Cudkowicz ME, Ferrante RJ. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler. 2009 Apr; 10(2):85-94.
    View in: PubMed
  47. Bedlack RS, Cudkowicz ME. Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance. Front Neurol Neurosci. 2009; 25:144-51.
    View in: PubMed
  48. Caraganis A, Benn S, Cudkowicz M, Brown RH. Thrombopoietin is ineffective in a mouse model of motor neuron disease. Amyotroph Lateral Scler. 2008 Dec; 9(6):354-8.
    View in: PubMed
  49. Qureshi M, Shui A, Dibernardo AB, Brown RH, Schoenfeld DA, Cudkowicz ME. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008 Dec; 9(6):369-74.
    View in: PubMed
  50. Badayan I, Cudkowicz ME. Is it too soon for mesenchymal stem cell trials in people with ALS? Amyotroph Lateral Scler. 2008 Dec; 9(6):321-2.
    View in: PubMed
  51. Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008 Oct; 5(4):516-27.
    View in: PubMed
  52. Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008 Oct; 9(5):257-65.
    View in: PubMed
  53. Qureshi M, Brown RH, Rogers JT, Cudkowicz ME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2008; 2:51-4.
    View in: PubMed
  54. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008 Jul; 38(1):837-44.
    View in: PubMed
  55. Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler. 2008 Jun; 9(3):131-40.
    View in: PubMed
  56. Meininger V, Shefner J, Cudkowicz M. Lithium therapy in ALS. Amyotroph Lateral Scler. 2008 Apr; 9(2):122.
    View in: PubMed
  57. Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, Cudkowicz ME, Furlong CE, Brown RH. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology. 2008 Mar 18; 70(12):929-34.
    View in: PubMed
  58. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol. 2008 Feb; 7(2):119-20; author reply 120-1.
    View in: PubMed
  59. McCormick AL, Brown RH, Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008 Jan 22; 70(4):278-83.
    View in: PubMed
  60. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler. 2008; 9(1):16-23.
    View in: PubMed
  61. Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH, Cudkowicz M, Gordon PH, Hardy J, Kasarskis EJ, Kaufmann P, Miller R, Sorenson E, Tandan R, Traynor BJ, Nash J, Sherman A, Mailman MD, Ostell J, Bruijn L, Cwik V, Rich SS, Singleton A, Refolo L, Andrews J, Zhang R, Conwit R, Keller MA. Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One. 2007; 2(12):e1254.
    View in: PubMed
  62. Rutkove SB, Zhang H, Schoenfeld DA, Raynor EM, Shefner JM, Cudkowicz ME, Chin AB, Aaron R, Shiffman CA. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol. 2007 Nov; 118(11):2413-8.
    View in: PubMed
  63. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007 Aug 21; 69(8):776-84.
    View in: PubMed
  64. Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May; 12(2):229-52.
    View in: PubMed
  65. Butsch PO, Cudkowicz ME. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis? Exp Neurol. 2007 Jul; 206(1):11-5.
    View in: PubMed
  66. Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion. 2007 Jun; 7 Suppl:S146-53.
    View in: PubMed
  67. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve. 2007 Feb; 35(2):228-34.
    View in: PubMed
  68. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology. 2007 Jan 2; 68(1):76-7.
    View in: PubMed
  69. Shefner JM, Cudkowicz M, Brown RH. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2006 Nov; 34(5):603-7.
    View in: PubMed
  70. Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006 Dec; 129(Pt 12):3384-90.
    View in: PubMed
  71. Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown RH, Cudkowicz ME. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006 Sep; 7(3):173-82.
    View in: PubMed
  72. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006 Jul 11; 67(1):20-7.
    View in: PubMed
  73. Lindhorst S, Cudkowicz M. Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Nat Clin Pract Neurol. 2006 Jul; 2(7):364-5.
    View in: PubMed
  74. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006 Jul; 60(1):22-31.
    View in: PubMed
  75. Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn. 2006 May; 6(3):387-98.
    View in: PubMed
  76. DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim Biophys Acta. 2006 Nov-Dec; 1762(11-12):1139-49.
    View in: PubMed
  77. Bruijn LI, Cudkowicz M. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother. 2006 Mar; 6(3):417-28.
    View in: PubMed
  78. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L. Identification of potential CSF biomarkers in ALS. Neurology. 2006 Apr 25; 66(8):1218-22.
    View in: PubMed
  79. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005 Dec 13; 65(11):1834-6.
    View in: PubMed
  80. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta. 2006 Mar; 1762(3):373-80.
    View in: PubMed
  81. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005 Dec; 95(5):1461-71.
    View in: PubMed
  82. Choudry RB, Cudkowicz ME. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J Clin Pharmacol. 2005 Dec; 45(12):1334-44.
    View in: PubMed
  83. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH, Ferrante RJ. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005 Jun; 93(5):1087-98.
    View in: PubMed
  84. Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH, Garson JA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005 Feb 8; 64(3):454-8.
    View in: PubMed
  85. Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of military service and mortality from ALS. Neurology. 2005 Jan 11; 64(1):32-7.
    View in: PubMed
  86. Ascherio A, Weisskopf MG, O'reilly EJ, Jacobs EJ, McCullough ML, Calle EE, Cudkowicz M, Thun MJ. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005 Jan; 57(1):104-10.
    View in: PubMed
  87. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004 Nov 23; 63(10):1933-5.
    View in: PubMed
  88. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D. A clinical trial of creatine in ALS. Neurology. 2004 Nov 9; 63(9):1656-61.
    View in: PubMed
  89. Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol. 2004; 52(3):141-4.
    View in: PubMed
  90. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve. 2004 Oct; 30(4):463-9.
    View in: PubMed
  91. Cudkowicz M, Zhang H, Qureshi M, Schoenfeld D. Maximum voluntary isometric contraction (MVIC). Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep; 5 Suppl 1:84-5.
    View in: PubMed
  92. Cudkowicz M, Shefner J. North East ALS Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep; 5 Suppl 1:125-7.
    View in: PubMed
  93. Minocycline safety and tolerability in Huntington disease. Neurology. 2004 Aug 10; 63(3):547-9.
    View in: PubMed
  94. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol. 2004 Jul 1; 160(1):26-33.
    View in: PubMed
  95. Cudkowicz ME, Schoenfeld D, Williams L. Improving the responsiveness of rating scales: the challenge of stepping twice into the same river. Neurology. 2004 May 25; 62(10):1666-7.
    View in: PubMed
  96. Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx. 2004 Apr; 1(2):273-83.
    View in: PubMed
  97. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003 Aug 26; 61(4):456-64.
    View in: PubMed
  98. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003 Aug; 43(3):191-6.
    View in: PubMed
  99. Al-Chalabi A, Scheffler MD, Smith BN, Parton MJ, Cudkowicz ME, Andersen PM, Hayden DL, Hansen VK, Turner MR, Shaw CE, Leigh PN, Brown RH. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Ann Neurol. 2003 Jul; 54(1):130-4.
    View in: PubMed
  100. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003 May 27; 60(10):1615-20.
    View in: PubMed
  101. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci. 2003 Mar 15; 207(1-2):71-6.
    View in: PubMed
  102. Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Exp Neurol. 2003 Feb; 179(2):229-35.
    View in: PubMed
  103. Cudkowicz ME, Pastusza KA, Sapp PC, Mathews RK, Leahy J, Pasinelli P, Francis JW, Jiang D, Andersen JK, Brown RH. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. Neurology. 2002 Sep 10; 59(5):729-34.
    View in: PubMed
  104. Dreibelbis JE, Brown RH, Pastuszak KA, Smith ER, Kaplan PL, Cudkowicz ME. Disease course unaltered by a single intracisternal injection of BMP-7 in ALS mice. Muscle Nerve. 2002 Jan; 25(1):122-3.
    View in: PubMed
  105. Shefner JM, Cudkowicz ME, Brown RH. Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle Nerve. 2002 Jan; 25(1):39-42.
    View in: PubMed
  106. Mandler RN, Anderson FA, Miller RG, Clawson L, Cudkowicz M, Del Bene M. The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Dec; 2(4):203-8.
    View in: PubMed
  107. Shefner JM, Brown RH, Cole D, Chaturvedi P, Schoenfeld D, Pastuszak K, Matthews R, Upton-Rice M, Cudkowicz ME. Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations. Neurology. 2001 Nov 27; 57(10):1857-61.
    View in: PubMed
  108. Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, Flint Beal M, Cudkowicz M. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000 Oct 1; 29(7):652-8.
    View in: PubMed
  109. Hausdorff JM, Lertratanakul A, Cudkowicz ME, Peterson AL, Kaliton D, Goldberger AL. Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. J Appl Physiol. 2000 Jun; 88(6):2045-53.
    View in: PubMed
  110. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000 Jan 25; 54(2):452-8.
    View in: PubMed
  111. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2000; 12(3):364-9.
    View in: PubMed
  112. Upton-Rice MN, Cudkowicz ME, Warren L, Mathew RK, Ren JM, Finklestein SP, Brown RH. Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1999 Dec; 46(6):934.
    View in: PubMed
  113. Cudkowicz ME, Sexton PM, Ellis T, Hayden DL, Gwilt PR, Whalen J, Brown RH. The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis. Neurology. 1999 Apr 22; 52(7):1492-4.
    View in: PubMed
  114. Montine TJ, Beal MF, Robertson D, Cudkowicz ME, Biaggioni I, O'Donnell H, Zackert WE, Roberts LJ, Morrow JD. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology. 1999 Mar 23; 52(5):1104-5.
    View in: PubMed
  115. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. Riluzole therapy in Huntington's disease (HD). Mov Disord. 1999 Mar; 14(2):326-30.
    View in: PubMed
  116. Upton-Rice MN, Cudkowicz ME, Mathew RK, Reif D, Brown RH. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice. Ann Neurol. 1999 Mar; 45(3):413-4.
    View in: PubMed
  117. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 1999 Feb; 52(3):562-5.
    View in: PubMed
  118. Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol. 1998 Jun; 43(6):703-10.
    View in: PubMed
  119. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord. 1998 May; 13(3):428-37.
    View in: PubMed
  120. Hausdorff JM, Edelberg HK, Cudkowicz ME, Singh MA, Wei JY. The relationship between gait changes and falls. J Am Geriatr Soc. 1997 Nov; 45(11):1406.
    View in: PubMed
  121. Cudkowicz ME, Warren L, Francis JW, Lloyd KJ, Friedlander RM, Borges LF, Kassem N, Munsat TL, Brown RH. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology. 1997 Jul; 49(1):213-22.
    View in: PubMed
  122. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997 Feb; 41(2):210-21.
    View in: PubMed
  123. Hausdorff JM, Mitchell SL, Firtion R, Peng CK, Cudkowicz ME, Wei JY, Goldberger AL. Altered fractal dynamics of gait: reduced stride-interval correlations with aging and Huntington's disease. J Appl Physiol. 1997 Jan; 82(1):262-9.
    View in: PubMed
  124. Cudkowicz ME, Brown RH. An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. J Neurol Sci. 1996 Aug; 139 Suppl:10-5.
    View in: PubMed
  125. Blumenfeld H, Cha JH, Cudkowicz ME. Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates. Neurology. 1996 Feb; 46(2):556-8.
    View in: PubMed
  126. Merkel PA, Koroshetz WJ, Irizarry MC, Cudkowicz ME. Cocaine-associated cerebral vasculitis. Semin Arthritis Rheum. 1995 Dec; 25(3):172-83.
    View in: PubMed
  127. Cudkowicz ME, Sayegh MH, Rennke HG. Membranous nephropathy in a patient with renal cell carcinoma. Am J Kidney Dis. 1991 Mar; 17(3):349-51.
    View in: PubMed
  128. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol. 1990 Feb; 27(2):200-4.
    View in: PubMed
  129. Cudkowicz M, De la Monte SM. Histogenesis and cell lineage analysis of medulloblastomas. J Neurol Sci. 1989 Dec; 94(1-3):221-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Cudkowicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_